A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study - PubMed (original) (raw)
Clinical Trial
. 1996 Oct 15;88(8):2841-51.
Affiliations
- PMID: 8874180
Free article
Clinical Trial
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
J K Weick et al. Blood. 1996.
Free article
Abstract
Interest in high-dose cytarabine (HDAC) for both induction and postremission therapy for acute myeloid leukemia (AML) prompted the Southwest Oncology Group (SWOG) to initiate a randomized trial comparing HDAC with standard-dose cytarabine (SDAC) for remission induction of previously untreated AML and to compare high-dose treatment versus conventional doses for consolidation therapy. Patients less than 65 years of age with de novo or secondary AML were randomized for induction between SDAC 200 mg/ m2/d for 7 days by continuous infusion or HDAC at 2 g/ m2 intravenously every 12 hours for 12 doses; both groups received daunorubicin (DNR) at 45 mg/m2/d intravenously for 3 days. Complete responders to SDAC were randomized to receive either two additional courses of SDAC plus DNR or one course of HDAC plus DNR. Complete responders to HDAC were nonrandomly assigned to receive one additional course of HDAC plus DNR. Of patients randomized between SDAC (n = 493) and HDAC (n = 172) induction, 361 achieved complete remission (CR). The CR rate was slightly poorer with HDAC: 55% versus 58% with SDAC for patients aged less than 50, and 45% (HDAC) versus 53% (SDAC) for patients aged 50 to 64 (age-adjusted one-tailed P = .96). With a median follow-up time of 51 months, survival was not significantly better with HDAC (P = .41); the estimated survival rate at 4 years was 32% (HDAC) versus 22% (SDAC) for those aged less than 50, and 13% (HDAC) versus 11% (SDAC) for those aged 50 to 64. However, relapse-free survival was somewhat better following HDAC Induction (P = .049): 33% (HDAC) versus 21% (SDAC) at 4 years for those aged less than 50, and 21% (HDAC) versus 9% (SDAC) for those aged 50 to 64. Induction with HDAC was associated with a significantly increased risk of fatal (P = .0033) and neurologic (P < .0001) toxicity. Among patients who achieved CR with SDAC, survival and disease-free survival (DFS) following consolidation randomization were not significantly better with HDAC compared with SDAC (P = .77 and .46, respectively). Patients who received both HDAC induction and consolidation had the best postremission outcomes; however, the proportion of CR patients who did not go on to protocol consolidation therapy was more than twice as high after HDAC induction compared with SDAC. Induction therapy with HDAC plus DNR was associated with greater toxicity than SDAC plus DNR, but with no improvement in CR rate or survival. Following CR induction with SDAC, consolidation with HDAC increased toxicity but not survival or DFS. In a nonrandomized comparison, patients who received both HDAC induction and consolidation had superior survival and DFS compared with those who received SDAC induction with either SDAC or HDAC consolidation.
Similar articles
- Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK).
Fopp M, Fey MF, Bacchi M, Cavalli F, Gmuer J, Jacky E, Schmid L, Tichelli A, Tobler A, Tschopp L, Von Fliedner V, Gratwohl A. Fopp M, et al. Ann Oncol. 1997 Mar;8(3):251-7. doi: 10.1023/a:1008267904952. Ann Oncol. 1997. PMID: 9137794 Clinical Trial. - Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R. Löwenberg B, et al. J Clin Oncol. 1998 Mar;16(3):872-81. doi: 10.1200/JCO.1998.16.3.872. J Clin Oncol. 1998. PMID: 9508168 Clinical Trial. - A randomized study of high-dose cytarabine in induction in acute myeloid leukemia.
Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der Weyden M, Lowenthal RM, Page F, Garson OM, Juneja S. Bishop JF, et al. Blood. 1996 Mar 1;87(5):1710-7. Blood. 1996. PMID: 8634416 Clinical Trial. - The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G, Bernasconi P, Boni M, Castoldi GL, Ciolli S, Clavio M, Cox MC, Cuneo A, Del Poeta G, Dini D, Falzetti D, Fanin R, Gobbi M, Isidori A, Leoni F, Liso V, Malagola M, Martinelli G, Mecucci C, Piccaluga PP, Petti MC, Rondelli R, Russo D, Sessarego M, Specchia G, Testoni N, Torelli G, Mandelli F, Tura S. Visani G, et al. Leukemia. 2001 Jun;15(6):903-9. doi: 10.1038/sj.leu.2402142. Leukemia. 2001. PMID: 11417475 Review. - A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care. Kimby E, et al. Acta Oncol. 2001;40(2-3):231-52. doi: 10.1080/02841860151116321. Acta Oncol. 2001. PMID: 11441935 Review.
Cited by
- Current status and research directions in acute myeloid leukemia.
Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, Kadia T, Sasaki K, Short NJ, Yilmaz M, Ravandi F. Kantarjian H, et al. Blood Cancer J. 2024 Sep 19;14(1):163. doi: 10.1038/s41408-024-01143-2. Blood Cancer J. 2024. PMID: 39300079 Free PMC article. Review. - Improved Treatment Outcomes With Modified Induction Therapy in Acute Myeloid Leukemia (AML): A Retrospective Observational Study From a Regional Cancer Center.
Iqbal A, Dubey M, Randhawa AS, Khanikar D, Hazarika M, Roy PS, Dutta C, Barbhuiyan S, Deka R. Iqbal A, et al. Cureus. 2024 Jan 31;16(1):e53303. doi: 10.7759/cureus.53303. eCollection 2024 Jan. Cureus. 2024. PMID: 38435958 Free PMC article. - Paradigm Shift in the Management of Acute Myeloid Leukemia-Approved Options in 2023.
Premnath N, Madanat YF. Premnath N, et al. Cancers (Basel). 2023 May 31;15(11):3002. doi: 10.3390/cancers15113002. Cancers (Basel). 2023. PMID: 37296964 Free PMC article. Review. - An Updated Overview of the Role of CYP450 during Xenobiotic Metabolization in Regulating the Acute Myeloid Leukemia Microenvironment.
Sandoval C, Calle Y, Godoy K, Farías J. Sandoval C, et al. Int J Mol Sci. 2023 Mar 23;24(7):6031. doi: 10.3390/ijms24076031. Int J Mol Sci. 2023. PMID: 37047003 Free PMC article. Review. - Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia.
Liu Q, Gao H, Li J, Hu Y, Wu L, Zhao X, Li S. Liu Q, et al. EJHaem. 2020 Aug 11;1(1):79-85. doi: 10.1002/jha2.76. eCollection 2020 Jul. EJHaem. 2020. PMID: 35847688 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources